Everolimus Versus Axitinib as Second‐line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy
暂无分享,去创建一个
B. Escudier | Y. Loriot | K. Fizazi | C. Massard | L. Albiges | L. Derosa | A. Guida
[1] E. Jonasch,et al. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review , 2016, Current medical research and opinion.
[2] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[3] P. Kantoff,et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[4] Billy Amzal,et al. An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed. , 2015, Clinical therapeutics.
[5] T. Choueiri,et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. , 2015, European urology.
[6] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[7] C. Kollmannsberger,et al. Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies , 2014, PloS one.
[8] T. Choueiri,et al. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. , 2014, Clinical genitourinary cancer.
[9] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[10] B. Escudier,et al. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. , 2013, European journal of cancer.
[11] Lauren McCann,et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.
[12] J. Larkin,et al. Current and future systemic treatments for renal cell carcinoma. , 2013, Seminars in cancer biology.
[13] R. Motzer,et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.
[14] Xin Huang,et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[16] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[17] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.